#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14754	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2067	707.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1404	1404	C	835	C	788	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14754	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2067	707.2	0	HET	.	.	.	C207T	.	207	207	C	427	427	C	840	C,T	625,153	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14754	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2067	707.2	0	HET	.	.	.	C451T	.	451	451	C	671	671	C	809	C,T	383,388	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27260	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3508	773.7	0	.	n	.	0	T695C	SNP	695	695	T	964	964	C	777	C,T	733,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27260	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3508	773.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2240	2240	C	889	C,A	821,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27260	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3508	773.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2314	2314	A	862	A	807	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27260	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3508	773.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2866	2866	C	823	C	755	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1994	folP	855	855	100.0	folP.l15.c4.ctg.1	1673	118.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1132	1134	AGC	199;199;200	A;G;C	190;189;188	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4926	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3362	146.0	1	SNP	p	S91F	1	.	.	271	273	TTC	583	585	TTC	162;165;164	T;T;C	155;157;155	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4926	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3362	146.0	1	SNP	p	G95N	0	.	.	283	285	GGC	595	597	GGC	167;167;168	G;G;C,T	161;159;158,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4926	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3362	146.0	1	SNP	p	D95G	1	.	.	283	285	GGC	595	597	GGC	167;167;168	G;G;C,T	161;159;158,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1520	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1311	115.0	1	SNP	p	G45D	0	.	.	133	135	GGC	487	489	GGC	199;198;198	G;G;C	182;182;183	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	802	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1051	75.7	0	.	n	.	0	A197.	DEL	197	197	A	570	570	A	188	A	175	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5852	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3153	185.2	1	SNP	p	D86N	0	.	.	256	258	GAC	672	674	GAC	235;230;229	G;A;C	219;209;213	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5852	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3153	185.2	1	SNP	p	S87R	1	.	.	259	261	CGT	675	677	CGT	231;235;235	C,A;G;T	213,2;221;215	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5852	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3153	185.2	1	SNP	p	R87W	0	.	.	259	261	CGT	675	677	CGT	231;235;235	C,A;G;T	213,2;221;215	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5852	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3153	185.2	1	SNP	p	R87I	0	.	.	259	261	CGT	675	677	CGT	231;235;235	C,A;G;T	213,2;221;215	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5852	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3153	185.2	1	SNP	p	S88P	0	.	.	262	264	TCC	678	680	TCC	233;231;234	T;C;C	219;216;218	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4090	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2697	151.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1603	1605	GGC	209;204;201	G;G;C	194;190;189	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1156	1158	GCC	195;198;192	G;C;C	187;191;185	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1159	1161	ATG	195;198;197	A;T,G;G	185;189,1;189	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1171	1173	ACC	195;197;199	A;C;C	183;187;189	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1171	1173	ACC	195;197;199	A;C;C	183;187;189	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1672	1674	ACC	199;200;199	A;C;C	177;183;183	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1726	1728	GCG	197;198;196	G;C;G	186;187;187	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1726	1728	GCG	197;198;196	G;C;G	186;187;187	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1849	1851	GGT	161;160;162	G;G;T	148;148;149	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1858	1860	AGC	149;147;147	A;G;C	143;142;140	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2285	173.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1876	1878	CCG	140;143;143	C,CG;C;G	110,1;111;112	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5830	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3247	179.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1638	1640	CCG	210;211;207	C;C;G	189;200;192	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2548	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1795	141.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	565	565	C	161	C,A	144,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2860	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1531	184.9	1	SNP	p	G120K	1	.	.	358	360	AAG	620	622	AAG	235;232;231	A;A;G	221;221;217	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2860	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1531	184.9	1	SNP	p	A121N	1	.	.	361	363	AAC	623	625	AAC	229;229;227	A;A;C	218;221;218	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2860	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1531	184.9	1	SNP	p	N121D	0	.	.	361	363	AAC	623	625	AAC	229;229;227	A;A;C	218;221;218	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10920	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4850	224.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1160	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1096	105.2	1	SNP	p	V57M	1	.	.	169	171	ATG	526	528	ATG	246;247;244	A;T;G,C	236;236;233,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
